济川药业(600566) - 2019 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 9.28% to CNY 510,176,114.21 year-on-year[4] - Operating income decreased by 2.26% to CNY 2,079,421,398.60 compared to the same period last year[4] - Basic earnings per share rose by 8.49% to CNY 0.626 compared to the previous year[4] - Total operating revenue for Q1 2019 was CNY 2,079,421,398.60, a decrease of 2.26% compared to CNY 2,127,605,139.83 in Q1 2018[16] - Net profit for Q1 2019 reached CNY 510,176,114.21, an increase of 9.25% from CNY 466,833,704.94 in Q1 2018[16] - Basic earnings per share for Q1 2019 was CNY 0.626, compared to CNY 0.577 in Q1 2018, representing an increase of 8.49%[16] Assets and Liabilities - Total assets increased by 10.20% to CNY 8,592,877,495.67 compared to the end of the previous year[4] - The total assets of the company reached ¥8,592,877,495.67, up from ¥7,797,322,407.83, indicating overall growth[14] - The total liabilities increased to ¥2,621,533,065.66 from ¥2,339,501,155.34, reflecting a rise in financial obligations[14] - Total liabilities as of March 31, 2019, amounted to CNY 558,010,207.98, an increase from CNY 554,457,162.29 at the end of 2018[15] - The total liabilities of the company amounted to CNY 2,339,501,155.34 as of the end of Q1 2019[24] Cash Flow - Net cash flow from operating activities increased by 13.12% to CNY 621,788,135.93 year-on-year[4] - In Q1 2019, the net cash flow from operating activities was CNY 621,788,135.93, an increase of 13.1% compared to CNY 549,672,444.26 in Q1 2018[18] - Total cash inflow from operating activities was CNY 2,195,446,447.09, slightly up from CNY 2,190,433,180.45 in the same period last year[18] - The company reported a net cash flow from investment activities of CNY -114,351,514.14, worsening from CNY -97,629,484.25 in Q1 2018[18] - Cash and cash equivalents at the end of Q1 2019 reached CNY 2,094,213,924.95, up from CNY 1,403,465,214.60 at the end of Q1 2018[18] - The net increase in cash and cash equivalents for Q1 2019 was CNY 507,312,639.89, compared to CNY 451,854,903.76 in Q1 2018[18] Shareholder Information - The total number of shareholders reached 28,865 by the end of the reporting period[7] - Jiangsu Jichuan Holding Group Co., Ltd. holds 51.14% of the shares, making it the largest shareholder[7] Government Support and Financial Changes - The company received government subsidies amounting to CNY 39,973,895.42 during the reporting period[5] - The fair value changes of financial assets resulted in a gain of CNY 3,957,132.07[6] - Financial expenses showed a significant decrease of 230.86%, resulting in a net income of -¥4,383,436.95 compared to ¥3,349,830.07, due to increased interest income[9] - Investment income decreased by 50.92% to ¥3,529,142.64 from ¥7,189,968.66, primarily due to a reduction in idle fundraising used for financial products[9] Other Financial Metrics - The weighted average return on equity decreased by 1.14 percentage points to 8.93%[4] - Employee compensation payable decreased by 33.19% to ¥95,710,805.30 from ¥143,260,924.15, primarily due to the payment of last year's year-end bonuses[9] - Tax payable increased by 44.97% to ¥150,223,174.60 from ¥103,620,995.83, reflecting an expansion in sales scale[9] - Other payables increased by 43.61% to ¥1,078,915,709.07 from ¥751,272,066.52, mainly due to an increase in reimbursements payable[9] - Research and development expenses for Q1 2019 were CNY 52,924,547.49, slightly up from CNY 52,665,973.50 in Q1 2018[16]